# Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1

> **NCT02687230** · PHASE1 · TERMINATED · sponsor: **BioNTech Research & Development, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Pancreatic Carcinoma
- Tumors That Express CA19-9

## Interventions

- **DRUG:** MVT-2163
- **DRUG:** MVT-5873

## Key facts

- **NCT ID:** NCT02687230
- **Lead sponsor:** BioNTech Research & Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07-11
- **Primary completion:** 2017-05-05
- **Final completion:** 2017-05-05
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2021-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02687230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02687230, "Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02687230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*